Success Metrics

Clinical Success Rate
87.5%

Based on 14 completed trials

Completion Rate
88%(14/16)
Active Trials
8(24%)
Results Posted
36%(5 trials)
Terminated
2(6%)

Phase Distribution

Ph phase_1
6
18%
Ph not_applicable
4
12%
Ph phase_2
13
38%
Ph early_phase_1
2
6%
Ph phase_3
4
12%

Phase Distribution

8

Early Stage

13

Mid Stage

4

Late Stage

Phase Distribution29 total trials
Early Phase 1First-in-human
2(6.9%)
Phase 1Safety & dosage
6(20.7%)
Phase 2Efficacy & side effects
13(44.8%)
Phase 3Large-scale testing
4(13.8%)
N/ANon-phased studies
4(13.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

77.8%

14 of 18 finished

Non-Completion Rate

22.2%

4 ended early

Currently Active

8

trials recruiting

Total Trials

34

all time

Status Distribution
Active(11)
Completed(14)
Terminated(4)
Other(5)

Detailed Status

Completed14
Recruiting5
unknown5
Active, not recruiting3
Not yet recruiting3
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
34
Active
8
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Early Phase 12 (6.9%)
Phase 16 (20.7%)
Phase 213 (44.8%)
Phase 34 (13.8%)
N/A4 (13.8%)

Trials by Status

completed1441%
withdrawn26%
recruiting515%
active_not_recruiting39%
not_yet_recruiting39%
terminated26%
unknown515%

Recent Activity

Clinical Trials (34)

Showing 20 of 34 trialsScroll for more
NCT03127774Phase 2

Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma

Active Not Recruiting
NCT07567573

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Completed
NCT05123807Phase 2

Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)

Recruiting
NCT05001880Phase 2

Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma

Recruiting
NCT05415709Early Phase 1

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Recruiting
NCT01815359Phase 2

ICARuS Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis

Active Not Recruiting
NCT03245892Phase 1

A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer

Completed
NCT04727242Phase 2

CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma

Active Not Recruiting
NCT06783491Phase 3

Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer

Not Yet Recruiting
NCT03188432Phase 2

Hyperthermic Intraperitoneal Chemotherapy Trial Comparing Quality of Life in Patients With Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed
NCT07177105Phase 2

Primary Tumor Resection With Sintilimab and Chemotherapy in Advanced NSCLC

Not Yet Recruiting
NCT06292286Not Applicable

Secondary Interval Cytoreductive Surgery in Platinum-sensitive Recurrent Epithelial Ovarian Cancer

Recruiting
NCT04213794Early Phase 1

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

Terminated
NCT05610826Phase 1

Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver

Withdrawn
NCT05375825Phase 1

Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin

Withdrawn
NCT02399410Phase 2

Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis

Completed
NCT06223763

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery

Unknown
NCT02567253Phase 2

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Completed
NCT05431530

Assessment of Quality of Life After Low Anterior Resection During Cytoreductive Surgery for Advanced Ovarian Cancer

Recruiting
NCT01257594Phase 1

EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas

Completed

Drug Details

Intervention Type
PROCEDURE
Total Trials
34